

MOF-mediated synthesis of CuO/CeO<sub>2</sub> composite nanoparticles: Characterization and estimation of the cellular toxicity against breast cancer cell line (MCF-7)

*Original*

MOF-mediated synthesis of CuO/CeO<sub>2</sub> composite nanoparticles: Characterization and estimation of the cellular toxicity against breast cancer cell line (MCF-7) / Farhangi, M. J.; Es-Haghi, A.; Yazdi, M. E. T.; Rahdar, A.; Bairo, F.. - In: JOURNAL OF FUNCTIONAL BIOMATERIALS. - ISSN 2079-4983. - ELETTRONICO. - 12:4(2021), p. 53. [10.3390/JFB12040053]

*Availability:*

This version is available at: 11583/2950083 since: 2022-02-17T13:54:32Z

*Publisher:*

MDPI

*Published*

DOI:10.3390/JFB12040053

*Terms of use:*

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

*Publisher copyright*

(Article begins on next page)



Article

# MOF-Mediated Synthesis of CuO/CeO<sub>2</sub> Composite Nanoparticles: Characterization and Estimation of the Cellular Toxicity against Breast Cancer Cell Line (MCF-7)

Mohammad Javad Farhangi<sup>1</sup>, Ali Es-haghi<sup>1</sup> , Mohammad Ehsan Taghavizadeh Yazdi<sup>2,\*</sup> , Abbas Rahdar<sup>3,\*</sup> and Francesco Baino<sup>4,\*</sup>

<sup>1</sup> Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad 91871-47578, Iran; Farhangi.mohamadjavad123@gmail.com (M.J.F.); ashaghi@gmail.com (A.E.-h.)

<sup>2</sup> Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad 91388-13944, Iran

<sup>3</sup> Department of Physics, University of Zabol, Zabol 98613-35856, Iran

<sup>4</sup> Institute of Materials Physics and Engineering, Applied Science and Technology Department, Politecnico di Torino, Corso Duca Degli Abruzzi 24, 10129 Torino, Italy

\* Correspondence: taghavizadehme971@mums.ac.ir (M.E.T.Y.); a.rahdar@uoz.ac.ir (A.R.); francesco.baino@polito.it (F.B.)



**Citation:** Farhangi, M.J.; Es-haghi, A.; Taghavizadeh Yazdi, M.E.; Rahdar, A.; Baino, F. MOF-Mediated Synthesis of CuO/CeO<sub>2</sub> Composite Nanoparticles: Characterization and Estimation of the Cellular Toxicity against Breast Cancer Cell Line (MCF-7). *J. Funct. Biomater.* **2021**, *12*, 53. <https://doi.org/10.3390/jfb12040053>

Academic Editor: Elisa Boanini

Received: 2 August 2021

Accepted: 24 September 2021

Published: 28 September 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** A copper oxide/cerium oxide nanocomposite (CuO/CeO<sub>2</sub>, NC) was synthesized via a novel method using a metal–organic framework as a precursor. This nanomaterial was characterized by Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), field emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), dynamic light scattering size analysis (DLS), and zeta potential. The PXRD showed the successful synthesis of the CuO/CeO<sub>2</sub> NC, in which the 2θ values of 35.55° (d = 2.52 Å, 100%) and 38.73° (d = 2.32 Å, 96%) revealed the existence of copper (II) oxide. FTIR analysis showed the CeO<sub>2</sub>, hydroxyl groups, absorbed water, and some residual peaks. The solid phase analysis by FESEM and TEM images showed mean particle sizes of 49.18 ± 24.50 nm and 30.58 ± 26.40 nm, respectively, which were comparable with crystallite size (38.4 nm) obtained from PXRD, but it appears the CuO/CeO<sub>2</sub> NC was not evenly distributed and in some areas, showed it was highly agglomerated. The hydrodynamic size (750.5 nm) also showed the agglomeration of the CuO/CeO<sub>2</sub> NCs in the solution, which had a negatively charged surface. The CuO/CeO<sub>2</sub> NCs showed anti-proliferative activity against human breast cancer cell line (MCF-7) in a dose- and time-dependence way, while affecting normal cells less significantly.

**Keywords:** nanomaterials; copper oxide; cerium oxide; metal–organic frameworks; anticancer; MCF-7

## 1. Introduction

The increased resistance of cancers to conventional treatments has become problematic [1–4]. The resistance of cancer cells to chemical drugs leads to a decrease in the response level of these cells to the drug and consequently the failure of the treatment. Therefore, the development of more effective drugs with few side effects and limitations is very important [5–8]. Nanotechnology can provide physicians with new strategies for directly targeting cancer cells and increasing drug efficacy [9,10]. Biomaterials are used in various cases such as drug delivery as well as imaging applications and have good potential for cancer diagnosis and treatment [11–14]. Pharmaceuticals can bind to nanoparticles (NPs) and the assemblies are specifically absorbed by the cancer cells by passive targeting. With this method, healthy cells are not exposed to pharmaceuticals and the side effects of the drug are reduced [15–17].

In this context, cerium oxide (ceria) nanoparticles are among the most promising. Recent studies have shown that this nanomaterial is cytotoxicity against cancer cells, so

further studies are important for determining side effects and its use in the treatment of cancers [18–21]. The popularity of cerium oxide ( $\text{CeO}_2$ ) is increasing in biomedical applications, which comes from the intrinsic properties of the ceria such as its oxidation–reduction behavior due to the surface oxygen vacancies and reversible valence state changes from Ce (III) to Ce (IV) [22,23]. The reduction of the particle size to nano-scale dimensions has a tremendous effect on its catalytic behavior. The expansion of synthesis methods that provide control over final morphology and size gives a new ability to this material, especially for medical-related applications [24–26]. Cerium oxide nanoparticles are widely used in various fields such as catalysis, gas sensors, fuel cells, hydrogen storage materials, optical devices, ultraviolet absorbents, polishing material, and many fields of biomedical science [27–36]. It has been proved that ceria nanoparticles are effective against oxidative stress and have an antioxidant role. Cerium oxide nanoparticles (nanoceria) are able to mimic the activity of superoxide dismutase and catalase due to changes in oxidation state [37,38]; therefore, these nanoparticles can be used as scavengers for reactive oxygen species (ROS) and inhibitors of the invasion and sensitization of cells to radiotherapy and chemotherapy [39–41]. Cerium oxide nanoparticles have cytotoxic effects against cancer cells and can induce apoptosis in them. One mechanism is cytochrome C release and caspase-3 and -9 activations. In fact, nanoceria increases apoptosis in cancer cells by the onset of mitochondrial cell death without chemical changes by targeting mitochondria [42]. In general, induction of programmed cell death or apoptosis is one of the most attractive approaches in cancer treatment. The cell death pathway can involve activation of proapoptotic events in the cell, which begin with the permeability of the mitochondrial membrane by Bax and Bak proteins, releasing cytochrome C from it and finally activating caspase-9 and then caspase-3 [43].

It was shown that the use of copper oxide nanoparticles, too, reduces the secretion of superoxide dismutase and catalase enzymes [44]. As oxidative stress was increased, the toxicity of nanoparticles was increased through ROS production. Therefore, copper oxide can be used as a dopant to adjust the antioxidant attributes, ROS production and catalytic activity of cerium oxide and make it more toxic against cancerous cells or bacteria. Mixed metal oxide nanocomposites (NCs) show characteristics of two metal oxides concurrently and may give an outstanding catalytic performance to the composite against cancer. Due to the importance of size, shape and morphology on the medical applications, the NCs produced in this study were analyzed comprehensively by investigating their physicochemical properties; cell toxicity tests with cancer cells were reported as well.

## 2. Materials and Methods

### 2.1. Reagents

All the chemicals and materials including terephthalic acid, dimethylformamide (DMF), ammonium cerium (IV) nitrate, and copper (II) nitrate trihydrate were procured from Sigma and Merck chemical groups unless otherwise stated.

### 2.2. Synthesis of the $\text{CuO/CeO}_2$ NCs Nanocomposites (NCs)

The precursor was prepared according to previous reports and used without any further purification [41]; the final  $\text{CuO/CeO}_2$  NCs were synthesized thermally for the first time. In brief, 1000 mg of terephthalic acid was sonicated in 34 mL of DMF until it was dissolved. Then, 3302 mg of ammonium cerium (IV) nitrate and 70 mg of copper (II) nitrate trihydrate were dissolved in DMF and added to the above mixture, which was stirred at 100 °C for 15 min. The formed precipitate was centrifuged, washed with DMF several times and dried in an oven at 80 °C. Then, 2 g of the prepared precursor was heated at 500 °C for 4 h. The obtained nanopowder underwent characterization and was used for anticancer experiments.

### 2.3. Characterization of Nanoparticles

The used techniques were transmission electron microscopy (TEM, ZEISS LEO 912 AB, Oberkochen, Germany) and field emission scanning electron microscopy (FESEM, TESCAN, MIRA 3, Brno, Czech Republic), which were used for the analyses of size and morphology (using an ultrasonic probe 20 kHz and 400 W power for 30 min to prepare the sample for analyses), Fourier transform infrared spectroscopy (FTIR, Shimadzu 8400, Kyoto, Japan) for determination of functional groups by using KBr pellet in the range of wave number ( $4000\text{--}400\text{ cm}^{-1}$ ), powder X-ray diffraction (PXRD, D8 ADVANCE-BRUKER) to determine the structure by using a Cu  $K\alpha$  radiation ( $\lambda = 1.5406\text{ \AA}$ ) within  $10\text{--}70^\circ$  ( $2\theta$ ) range, dynamic light scattering size analysis (DLS, Particle Size Analyzer, Vasco3, Cordouan Technologies, Pessac, France) for the measurement of hydrodynamic sizes using a 100 mg/L concentration of the nanoparticles, and Zeta-potential (Zeta Compact, CAD) for the assessment of surface charges.

### 2.4. In Vitro Cellular Tests

Human breast carcinoma cell line (MCF-7) was selected as a suitable in vitro model of solid tumors. MCF-7 cells were achieved from Pasteur Institute, Iran and was grown in Dulbecco's Modified Eagle Medium (DMEM) including 10 percentages of fetal bovine serum (FBS), 1 percentage of antibiotic (Pen/Str), and it was kept at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$ , and 95% humidity. The cells were treated with different concentrations (0.031, 0.062, 0.125, 0.250, 0.500, and 1.000  $\mu\text{g/mL}$ ) of synthesized CuO/CeO<sub>2</sub> NCs at three time points (24, 48, and 72 h). After incubation, the cell state was observed using a microscope, and later, 20  $\mu\text{L}$  MTT substance was added and incubated. A 96-cell plate reader was used to estimate the absorbance at 570 nanometer and the cell vitality percentage amount was calculated. Mouse embryonic fibroblasts (NIH-3T3) cell lines were used as normal cells and cultured under the same conditions described above.


### 2.5. Statistical Analysis

Data were analyzed using GraphPad Prism 6.0 (GraphPad software, Inc., San Diego, CA, USA). Data were presented as mean  $\pm$  standard deviation of at least three independent experiments. Student's *t*-test was performed for comparison between groups.  $p < 0.05$  was considered statistically significant.

## 3. Results and Discussion

### 3.1. Fourier-Transform Infrared Spectroscopy (FTIR)


The FTIR spectrum of the CuO/CeO<sub>2</sub> NCs was recorded from  $400$  to  $4000\text{ cm}^{-1}$  to analyze the functional groups (Figure 1). The observed band at  $3437\text{ cm}^{-1}$  was associated with absorbed water or hydroxyl groups on the surface. The appeared bands at  $2800\text{--}3000\text{ cm}^{-1}$  is related to the presence of methylene groups from the residual organic groups after calcination [45]. The absorption band at  $1621\text{ cm}^{-1}$  corresponded to the bending vibration of the hydroxyl groups or the absorbed H<sub>2</sub>O [46,47]. The peaks area under  $800\text{ cm}^{-1}$  was related to Ce-O or Cu-O bond vibrations [48]. The bands at  $1319\text{ cm}^{-1}$  and  $1059\text{ cm}^{-1}$  could show the vibrational modes of Ce-O-Ce [49].



**Figure 1.** The FTIR spectrum of the CuO/CeO<sub>2</sub> NCs (1, absorbed H<sub>2</sub>O or O–H stretching; 2, C–H stretching; 3, O–H stretching; 4, Ce–O–Ce vibration; 5, Ce–O/Cu–O vibration).

### 3.2. Powder X-ray Diffraction (PXRD)

The PXRD analysis was performed to investigate the structural changes after copper doping (Figure 2). CeO<sub>2</sub> and CuO were compatible with reference codes of 00-004-0593 and 00-005-0661, respectively. It appears that the crystal system of CeO<sub>2</sub> NPs was cubic and associated with 2 $\theta$  values of 28.55° ( $d = 3.12 \text{ \AA}$ , 100%), 33.08° ( $d = 2.71 \text{ \AA}$ , 29%), 47.49° ( $d = 1.91 \text{ \AA}$ , 51%), 56.33° ( $d = 1.63 \text{ \AA}$ , 44%), 59.10° ( $d = 1.56 \text{ \AA}$ , 5%) and 69.41° ( $d = 1.35 \text{ \AA}$ , 5%) and hkl values of (111), (200), (220), (311), (222), and (400) respectively. The experimental values of CeO<sub>2</sub> NPs were 28.63° ( $d = 3.12 \text{ \AA}$ , 99.5%), 33.15° ( $d = 2.70 \text{ \AA}$ , 34%), 47.51° ( $d = 1.91 \text{ \AA}$ , 100%), 56.44° ( $d = 1.63 \text{ \AA}$ , 95%), 59.04° ( $d = 1.56 \text{ \AA}$ , 18%), and 69.53° ( $d = 1.35 \text{ \AA}$ , 16%), and the values of CuO/CeO<sub>2</sub> NCs were 28.58° ( $d = 3.12 \text{ \AA}$ , 86%), 33.26° ( $d = 2.69 \text{ \AA}$ , 28%), 35.61° ( $d = 2.52 \text{ \AA}$ , 6%), 38.85° ( $d = 2.32 \text{ \AA}$ , 5.5%), 47.60° ( $d = 1.91 \text{ \AA}$ , 100%), 56.42° ( $d = 1.63 \text{ \AA}$ , 91%), 59.17° ( $d = 1.56 \text{ \AA}$ , 17%), and 69.55° ( $d = 1.35 \text{ \AA}$ , 7%). The results showed the phase purity of CeO<sub>2</sub> NPs. The 2 $\theta$  values of 35.61° and 38.85° in CuO/CeO<sub>2</sub> NCs were ascribed to the copper oxide with a monoclinic structure and reference code of 00-005-0661, which were associated to the 2 $\theta$  values of 35.55° ( $d = 2.52 \text{ \AA}$ , 100%) and 38.73° ( $d = 2.32 \text{ \AA}$ , 96%), and hkl values of (−111) and (111), respectively. Hence, it can be concluded that CuO/CeO<sub>2</sub> NCs were successfully synthesized after calcination. No additional peaks were observed other than those of CuO and CeO<sub>2</sub>, which indicated the phase purity of the prepared NCs. The crystallite sizes obtained by the Scherrer's equation using the most intense peaks were 32.9 nm and 38.4 nm for CeO<sub>2</sub> NPs and CuO/CeO<sub>2</sub> NCs, respectively. It appears that the crystallite size was increased after copper doping into the CeO<sub>2</sub> nanostructures.




**Figure 2.** PXRD analyses of the CeO<sub>2</sub> NPs and CuO/CeO<sub>2</sub> NCs. \* highlight the peaks interpreted according to the bottom part of the figure.

### 3.3. Field Emission Scanning Electron Microscopy (FESEM)

The FESEM images were used to analyze the morphology of the NCs (Figure 3). It appears that the particles have a spherical morphology and the mean particle size of the CuO/CeO<sub>2</sub> NCs was  $49.18 \pm 24.50$  nm. The particle sizes were determined by ImageJ software (bundled with Java 1.8.0\_172) and particle size analyses were performed using IBM SPSS statistics 22. The maximum, minimum, and overall ranges were 189.73 nm, 12.55 nm and 177.18 nm, respectively. The median (44.15 nm) was less than the mean size


of the NCs and greater than the mode (27.46 nm), which indicated a positively skewed frequency distribution and the skewness was 1.78. The difference between crystallite size (38.4 nm) and the mean particle size obtained from FESEM images (49.18 nm) indicated very low aggregation. The EDX analysis also showed the elemental composition of the copper and cerium in NC. The O K $\alpha$ , Ce L $\alpha$ , and Cu K $\alpha$  were the most intense peaks related to oxygen, cerium and copper, respectively, which appeared at 0.53, 4.82, and 8.01 keV.



**Figure 3.** (a) FESEM images, (b) particle size distribution and (c) EDX analysis of the CuO/CeO<sub>2</sub> NCs.

### 3.4. Transmission Electron Microscopy (TEM)

The TEM images (Figure 4) showed that CuO/CeO<sub>2</sub> NCs were spherical and the particle diameter was  $30.58 \pm 26.40$  nm. It appears that the mode, median, and mean showed the following order: mode < median < mean (13 < 22.98 < 30.58 nm), which indicated a positively skewed frequency distribution and skewness was 2.76. The minimum and maximum were calculated to be 8.22 nm and 170.73 nm, respectively. Although the difference between crystallite size (38.4 nm) and the grain sizes obtained from TEM images (30.6 nm) suggests low agglomeration, the presence of large particle (~178 nm) indicated that the CuO/CeO<sub>2</sub> NCs were not evenly distributed and the sample was highly agglomerated at some points. Therefore, the CuO/CeO<sub>2</sub> NCs were well-sonicated before undergoing biological in vitro tests.




**Figure 4.** TEM images (a–d) and particle size distribution (e) of the CuO/CeO<sub>2</sub> NCs.

### 3.5. Dynamic Light Scattering (DLS) and Zeta Potential

The DLS analysis (Figure 5) showed that CuO/CeO<sub>2</sub> NCs were highly agglomerated. Compared to the solid-state size, the hydrodynamic size (750.5 nm) was more than 15- and 24-times greater than the mean sizes obtained from FESEM and TEM images, respectively. The measurement of the hydrodynamic particle sizes presented the sizes of the largest

particles in the solution. The weak interactions of the solvent such as hydrogen bonds with the surface of the CuO/CeO<sub>2</sub> NCs led to the formation of layers of waters, aggregation of smaller particles or maybe other ionic components around the NCs. Therefore, the increased hydrodynamic size is reasonable. The Zeta potential was also assessed to be −20.0 mV, which was due to the presence of the hydroxyl or maybe the carboxyl groups on the surface of the CuO/CeO<sub>2</sub> NCs. Previous reports also suggest that zeta potentials lower than 25 mV would yield a high degree of colloidal stability [50]. Interestingly, the hydrodynamic sizes were much higher than what is expected due to zeta potential. The only rational reason could be the limitations of the DLS analyzer, which can only be sensitive to larger particles. As the TEM result showed, the particles with sizes of nearly 180 nm were observed in the solid phases. Therefore, due to the limitations of the DLS device and the presence of larger particles, it can be concluded that the obtained particle size was plausible.




**Figure 5.** Dynamic light scattering (DLS) of CuO/CeO<sub>2</sub> NCs.

### 3.6. Anti-Proliferative Activity of CuO/CeO<sub>2</sub> NCs against Breast Cancer Cell Lines

Cancer is a leading cause of death and a worldwide health problem [51]. Cancer is a disease characterized by uncontrolled cell proliferation that spreads from an initial focal point to other parts of the body to cause death [52,53]. In the past few decades, the application of nanocomposites in cell toxicity and anticancer properties has attracted a lot of attention with several nanoparticle types being used [54]. In this study, the cell toxicity effect of synthesized CeO<sub>2</sub>-CuO-NPs was measured through MTT assay against a breast cancer cell line (MCF-7) and normal fibroblastic cells. The result of the cytotoxic effect of synthesized nanoparticles (0.031–1.000 µg/mL) is shown in Figure 6 after 24, 48, and 72 h incubation. The results showed that there was a gradual decrease in cell vitality with increasing NC concentration, and this effect was more pronounced for longer incubation times using higher NC concentrations. This trend is clearly visible in cancer cells, where there is a marked decrease of cell viability over time if the NC concentration exceeds 0.250 µg/mL). Overall, the destruction of cancer cells occurs in a state dependent on both concentrations of CuO/CeO<sub>2</sub> NC and time of exposure. On the contrary, normal fibroblastic

cells seem to be less sensitive to the presence of NC. These results are in accordance with the findings reported in some previous studies that are briefly described below.



**Figure 6.** Cytotoxic activity of synthesized CuO/CeO<sub>2</sub> NCs against normal cell lines (NIH-3T3), and human breast cancer cell line (MCF-7). The percentages are shown as relative to control cells.

Es-haghi et al. studied the cell toxicity of CeO NPs and expression of antioxidant genes against liver cancerous cell lines [55]. They found that the biosynthesized cerium nanoparticles had little effect on normal cells (HUVEC) while being able to significantly kill cancer cells. The expression of catalase and superoxide desmutase genes was also increased in this regard. In another research the cytotoxicity of biosynthesized CeO<sub>2</sub> NPs against MCF-7 breast cancer cell line was investigated. The results of this study revealed the significant inhibitory effects of CeO<sub>2</sub> NPs on the growth of MCF-7 cells which depended on the concentration and time of treatment [56]. Ahmed et al. studied the effect of CuFe<sub>2</sub>O<sub>4</sub>

NPs against MCF-7 cells. The results showed that the generation of ROS by NPs is generally considered to a major contributor to NPs toxicity [57].

The metabolic features of cancerous cells are not the same as normal cells and, consequently, this can lead to different results in cellular toxicity between normal and cancer cells [3]. Today it is realized that the higher permeation retaining, reduced lymphatic drainage and vasculature leaking of cancerous cells enable the accumulation injected NPs in the tumor tissue [58]. In vitro studies confirmed that CuO NPs cause apoptosis in tumor cells [59]. One of the mechanisms by which CuO NPs destroy cancer cells is the production of reactive hydroxyl ions, which damage the DNA of cancer cells [60]. Another mechanism performed by CuO involves inhibition of Nuclear Factor (NF)- $\kappa$ B (NF- $\kappa$ B). NF- $\kappa$ B has been displayed to have a role in cancer, and so inhibition of this factor plays a significant function in the inhibition of cancer [61].

#### 4. Conclusions

CuO/CeO<sub>2</sub> NCs were successfully synthesized and analyzed from physical and biological viewpoints. It appears the metal–organic framework-based materials as precursors for the synthesis of the metal oxide is a useful and facile method, especially in the synthesis of the mixed metal oxides. The nature of composition and crystalline phases were confirmed by EDX and PXRD analyses. The mean size of composite nanoparticles was 49.18 and 30.58 nm as assessed by FESEM and TEM, respectively. The synthesized CuO/CeO<sub>2</sub> NC showed cell toxicity properties towards breast cancerous cell lines (MCF-7) in a dose- and time-dependence manner, while the toxicity of CuO/CeO<sub>2</sub> NC was significantly lower on normal fibroblastic cells.

**Author Contributions:** Conceptualization, A.R.; methodology, M.J.F., A.E.-h., M.E.T.Y. and A.R.; investigation, M.J.F., A.E.-h., M.E.T.Y. and A.R.; resources, M.J.F., A.E.-h., M.E.T.Y., A.R. and F.B.; writing—original draft preparation, M.J.F., A.E.-h., M.E.T.Y. and A.R.; writing—review and editing, F.B.; supervision, A.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data are included within this article.

**Conflicts of Interest:** The authors declare that they have no known competing interest.

#### References

1. Zhou, G.; Latchoumanin, O.; Hebbard, L.; Duan, W.; Liddle, C.; George, J.; Qiao, L. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. *Adv. Drug Deliv. Rev.* **2018**, *134*, 107–121. [[CrossRef](#)]
2. Yazdi, M.E.T.; Darroudi, M.; Amiri, M.S.; Hosseini, H.A.; Nourbakhsh, F.; Mashreghi, M.; Farjadi, M.; Kouhi, S.M.M.; Mousavi, S.H. Anticancer, antimicrobial, and dye degradation activity of biosynthesised silver nanoparticle using *Artemisia kopetdaghensis*. *Micro Nano Lett.* **2020**, *15*, 1046–1050. [[CrossRef](#)]
3. Yazdi, M.E.T. Ultrasound-based synthesis of ZnO Ag<sub>2</sub>O<sub>3</sub> nanocomposite: Characterization and evaluation of its antimicrobial and anticancer properties. *Res. Chem. Intermed.* **2021**, *47*, 1285–1296. [[CrossRef](#)]
4. Es-Haghi, A.; Yazdi, M.T.; Sharifalhoseini, M.; Baghani, M.; Yousefi, E.; Rahdar, A.; Bains, F. Application of Response Surface Methodology for Optimizing the Therapeutic Activity of ZnO Nanoparticles Biosynthesized from *Aspergillus niger*. *Biomimetics* **2021**, *6*, 34. [[CrossRef](#)]
5. Huang, W.; Lang, Y.; Hakeem, A.; Lei, Y.; Gan, L.; Yang, X. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers. *Int. J. Nanomed.* **2018**, *13*, 1723–1736. [[CrossRef](#)]
6. Thapa, R.K.; Byeon, J.H.; Choi, H.-G.; Yong, C.S.; Kim, J.O. PEGylated lipid bilayer-wrapped nano-graphene oxides for synergistic co-delivery of doxorubicin and rapamycin to prevent drug resistance in cancers. *Nanotechnology* **2017**, *28*, 295101. [[CrossRef](#)]
7. Taghavizadeh Yazdi, M.; Darroudi, M.; Amiri, M.S.; Zarrinfar, H.; Hosseini, H.A.; Mashreghi, M.; Mozafarri, H.; Ghorbani, A.; Mousavi, S.H. Antimycobacterial, anticancer, antioxidant, and photocatalytic activity of biosynthesized silver nanoparticles using *Berberis integerrima*. *Iran. J. Sci. Technol. Trans. A Sci.* **2021**. [[CrossRef](#)]

8. Mobaraki, F.M.M.; Taghavizadeh Yazdi, M.E.; Meshkat, Z.; Silanian Toosi, M.; Hosseini, S.M. Plant-derived synthesis and characterization of gold nanoparticles: Investigation of its antioxidant and anticancer activity against human testicular embryonic carcinoma stem cells. *Process. Biochem.* **2021**, *111*, 167–177. [[CrossRef](#)]
9. Seidi, K.; Neubauer, H.; Moriggl, R.; Jahanban-Esfahlan, R.; Javaheri, T. Tumor target amplification: Implications for nano drug delivery systems. *J. Control. Release* **2018**, *275*, 142–161. [[CrossRef](#)]
10. Jelonek, K.; Zajdel, A.; Wilczok, A.; Latocha, M.; Musiał-Kulik, M.; Forys, A.; Kasperczyk, J. Dual-targeted biodegradable micelles for anticancer drug delivery. *Mater. Lett.* **2019**, *241*, 187–189. [[CrossRef](#)]
11. Liu, Y.; Bhattarai, P.; Dai, Z.; Chen, X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. *Chem. Soc. Rev.* **2018**, *48*, 2053–2108. [[CrossRef](#)]
12. Muthu, M.S.; Mei, L.; Feng, S.-S. Nanotheranostics: Advanced nanomedicine for the integration of diagnosis and therapy. *Nanomedicine* **2014**, *9*, 1277–1280. [[CrossRef](#)]
13. Sun, K.; Xu, C.; Hu, T.; Lin, C.; Wang, Y.; Li, Y.; Li, L.; Wang, Y.  $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>/La-MOFs@SiO<sub>2</sub> for magnetic resonance/fluorescence dual mode imaging and pH-drug delivery. *Mater. Lett.* **2018**, *228*, 216–219. [[CrossRef](#)]
14. Hashemzadeh, M.R.; Yazdi, M.E.T.; Amiri, M.S.; Mousavi, S.H. Stem cell therapy in the heart: Biomaterials as a key route. *Tissue Cell* **2021**, *71*, 101504. [[CrossRef](#)]
15. Bazak, R.; Hourri, M.; El Achy, S.; Hussein, W.; Refaat, T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. *Mol. Clin. Oncol.* **2014**, *2*, 904–908. [[CrossRef](#)]
16. Clemons, T.D.; Singh, R.; Sorolla, A.; Chaudhari, N.; Hubbard, A.; Iyer, K.S. Distinction between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy. *Langmuir* **2018**, *34*, 15343–15349. [[CrossRef](#)]
17. Dhamecha, D.; Jalalpure, S.; Jadhav, K.; Jagwani, S.; Chavan, R. Doxorubicin loaded gold nanoparticles: Implication of passive targeting on anticancer efficacy. *Pharmacol. Res.* **2016**, *113*, 547–556. [[CrossRef](#)]
18. Abbas, F.; Jan, T.; Iqbal, J.; Ahmad, I.; Naqvi, M.S.H.; Malik, M. Facile synthesis of ferromagnetic Ni doped CeO<sub>2</sub> nanoparticles with enhanced anticancer activity. *Appl. Surf. Sci.* **2015**, *357*, 931–936. [[CrossRef](#)]
19. Wu, X.; Zhang, Y.; Lu, Y.; Pang, S.; Yang, K.; Tian, Z.; Pei, Y.; Qu, Y.; Wang, F.; Pei, Z. Synergistic and targeted drug delivery based on nano-CeO<sub>2</sub> capped with galactose functionalized pillar [5] arene via host–guest interactions. *J. Mater. Chem. B* **2017**, *5*, 3483–3487. [[CrossRef](#)]
20. Ashna, M.; Es-Haghi, A.; Noghondar, M.K.; Al Amara, D.; Yazdi, M.E.T. Greener synthesis of cerium oxide nanoemulsion using pollen grains of Brassica napus and evaluation of its antitumour and cytotoxicity properties. *Mater. Technol.* **2021**. [[CrossRef](#)]
21. Rahdar, A.; Aliahmad, M.; Samani, M.; Majd, M.H.; Susan, A.B.H. Synthesis and characterization of highly efficacious Fe-doped ceria nanoparticles for cytotoxic and antifungal activity. *Ceram. Int.* **2019**, *45*, 7950–7955. [[CrossRef](#)]
22. Sadidi, H.; Hooshmand, S.; Ahmadabadi, A.; Hosseini, S.J.; Baino, F.; Vatanpour, M.; Kargozar, S. Cerium Oxide Nanoparticles (Nanoceria): Hopes in Soft Tissue Engineering. *Molecules* **2020**, *25*, 4559. [[CrossRef](#)]
23. Kargozar, S.; Baino, F.; Hoseini, S.J.; Hamzehlou, S.; Darroudi, M.; Verdi, J.; Hasanazadeh, L.; Kim, H.-W.; Mozafari, M. Biomedical applications of nanoceria: New roles for an old player. *Nanomedicine* **2018**, *13*, 3051–3069. [[CrossRef](#)]
24. Pesaraklou, A.; Matin, M.M. Cerium oxide nanoparticles and their importance in cell signaling pathways for predicting cellular behavior. *Nanomedicine* **2020**, *15*, 1709–1718. [[CrossRef](#)] [[PubMed](#)]
25. Celardo, I.; Pedersen, J.Z.; Traversa, E.; Ghibelli, L. Pharmacological potential of cerium oxide nanoparticles. *Nanoscale* **2011**, *3*, 1411–1420. [[CrossRef](#)]
26. Amiri, M.; Mohammadzadeh, V.; Yazdi, M.; Barani, M.; Rahdar, A.; Kyzas, G. Plant-Based Gums and Mucilages Applications in Pharmacology and Nanomedicine: A Review. *Molecules* **2021**, *26*, 1770. [[CrossRef](#)]
27. Nadeem, M.; Khan, R.; Afridi, K.; Nadhman, A.; Ullah, S.; Faisal, S.; Mabood, Z.U.; Hano, C.; Abbasi, B.H. Green Synthesis of Cerium Oxide Nanoparticles (CeO<sub>2</sub> NPs) and Their Antimicrobial Applications: A Review. *Int. J. Nanomed.* **2020**, *15*, 5951–5961. [[CrossRef](#)]
28. Papavasiliou, J.; Paxinou, A.; Stowik, G.; Neophytides, S.; Avgouropoulos, G. Steam Reforming of Methanol over Nanostructured Pt/TiO<sub>2</sub> and Pt/CeO<sub>2</sub> Catalysts for Fuel Cell Applications. *Catalysts* **2018**, *8*, 544. [[CrossRef](#)]
29. Ghouri, Z.K.; Barakat, N.; Kim, H.Y.; Park, M.; Khalil, K.A.; El-Newehy, M.H.; Al-Deyab, S.S. Nano-engineered ZnO/CeO<sub>2</sub> dots@CNFs for fuel cell application. *Arab. J. Chem.* **2016**, *9*, 219–228. [[CrossRef](#)]
30. Chen, Y.; Li, Z.; Miao, N. Polymethylmethacrylate (PMMA)/CeO<sub>2</sub> hybrid particles for enhanced chemical mechanical polishing performance. *Tribol. Int.* **2015**, *82*, 211–217. [[CrossRef](#)]
31. Latha, P.; Dhanabackialakshmi, R.; Kumar, P.S.; Karuthapandian, S. Synergistic effects of trouble free and 100% recoverable CeO<sub>2</sub> /Nylon nanocomposite thin film for the photocatalytic degradation of organic contaminants. *Sep. Purif. Technol.* **2016**, *168*, 124–133. [[CrossRef](#)]
32. Kanakaraju, S.; Mohan, S.; Sood, A. Optical and structural properties of reactive ion beam sputter deposited CeO<sub>2</sub> films. *Thin Solid Films* **1997**, *305*, 191–195. [[CrossRef](#)]
33. Singh, G.P.; Kaur, P.; Kaur, S.; Singh, D.P. Investigation of structural, physical and optical properties of CeO<sub>2</sub>–Bi<sub>2</sub>O<sub>3</sub>–B<sub>2</sub>O<sub>3</sub> glasses. *Phys. B Condens. Matter* **2012**, *407*, 4168–4172. [[CrossRef](#)]
34. Sangsefidi, F.S.; Salavati-Niasari, M.; Khojasteh, H.; Shabani-Nooshabadi, M. Synthesis, characterization and investigation of the electrochemical hydrogen storage properties of CuO–CeO<sub>2</sub> nanocomposites synthesized by green method. *Int. J. Hydrog. Energy* **2017**, *42*, 14608–14620. [[CrossRef](#)]

35. Izu, N.; Shin, W.; Murayama, N.; Kanzaki, S. Resistive oxygen gas sensors based on CeO<sub>2</sub> fine powder prepared using mist pyrolysis. *Sens. Actuators B Chem.* **2002**, *87*, 95–98. [[CrossRef](#)]
36. Wang, J.; Li, Z.; Zhang, S.; Yan, S.; Cao, B.; Wang, Z.; Fu, Y. Enhanced NH<sub>3</sub> gas-sensing performance of silica modified CeO<sub>2</sub> nanostructure based sensors. *Sens. Actuators B Chem.* **2018**, *255*, 862–870. [[CrossRef](#)]
37. Akhtar, M.J.; Ahamed, M.; Alhadlaq, H.; Khan, M.M.; Alrokayan, S. Glutathione replenishing potential of CeO<sub>2</sub> nanoparticles in human breast and fibrosarcoma cells. *J. Colloid Interface Sci.* **2015**, *453*, 21–27. [[CrossRef](#)] [[PubMed](#)]
38. Shi, X.; Yang, J.; Wen, X.; Tian, F.; Li, C. Oxygen vacancy enhanced biomimetic superoxide dismutase activity of CeO<sub>2</sub>-Gd nanozymes. *J. Rare Earths* **2020**, *39*, 1108–1116. [[CrossRef](#)]
39. Gao, Y.; Gao, F.; Chen, K.; Ma, J.-L. Cerium oxide nanoparticles in cancer. *OncoTargets Ther.* **2014**, *7*, 835–840. [[CrossRef](#)]
40. Tian, Z.; Li, X.; Ma, Y.; Chen, T.; Xu, D.; Wang, B.; Qu, Y.; Gao, Y. Quantitatively Intrinsic Biomimetic Catalytic Activity of Nanocerias as Radical Scavengers and Their Ability against H<sub>2</sub>O<sub>2</sub> and Doxorubicin-Induced Oxidative Stress. *ACS Appl. Mater. Interfaces* **2017**, *9*, 23342–23352. [[CrossRef](#)]
41. Das, S.; Dowding, J.M.; Klump, K.E.; McGinnis, J.F.; Self, W.; Seal, S. Cerium oxide nanoparticles: Applications and prospects in nanomedicine. *Nanomedicine* **2013**, *8*, 1483–1508. [[CrossRef](#)]
42. Arya, A.; Sethy, N.; Das, M.; Singh, S.K.; Das, A.; Ujjain, S.K.; Sharma, R.K.; Sharma, M.; Bhargava, K. Cerium oxide nanoparticles prevent apoptosis in primary cortical culture by stabilizing mitochondrial membrane potential. *Free. Radic. Res.* **2014**, *48*, 784–793. [[CrossRef](#)]
43. Lalier, L.; Cartron, P.-F.; Juin, P.; Nedelkina, S.; Manon, S.; Bechinger, B.; Vallette, F. Bax activation and mitochondrial insertion during apoptosis. *Apoptosis* **2007**, *12*, 887–896. [[CrossRef](#)] [[PubMed](#)]
44. Tunçsoy, M.; Duran, S.; Cıçık, B.; Erdem, C. Effects of Copper Oxide Nanoparticles on Antioxidant Enzyme Activities and on Tissue Accumulation of Oreochromis niloticus. *Bull. Environ. Contam. Toxicol.* **2017**, *99*, 360–364. [[CrossRef](#)] [[PubMed](#)]
45. Nourmohammadi, E.; Oskuee, R.K.; Hasanzadeh, L.; Mohajeri, M.; Hashemzadeh, A.; Rezayi, M.; Darroudi, M. Cytotoxic activity of greener synthesis of cerium oxide nanoparticles using carrageenan towards a WEHI 164 cancer cell line. *Ceram. Int.* **2018**, *44*, 19570–19575. [[CrossRef](#)]
46. Zamiri, R.; Abbastabar Ahangar, H.; Kaushal, A.; Zakaria, A.; Zamiri, G.; Tobaldi, D.; Ferreira, J.M. Dielectrical properties of CeO<sub>2</sub> nanoparticles at different temperatures. *PLoS ONE* **2015**, *10*, e0122989.
47. Dezfuli, A.S.; Ganjali, M.R.; Naderi, H.R.; Norouzi, P. A high performance supercapacitor based on a ceria/graphene nanocomposite synthesized by a facile sonochemical method. *RSC Adv.* **2015**, *5*, 46050–46058. [[CrossRef](#)]
48. Karimi, A.; Fatehifar, E.; Alizadeh, R. Synthesis and characterization of nanostructured CuO/CeO<sub>2</sub> catalysts via ultrasound assisted techniques used for selective oxidation of CO. *Iran. J. Chem. Eng.* **2013**, *10*, 51–59.
49. Sabzehmeidani, M.M.; Karimi, H.; Ghaedi, M. Visible light-induced photo-degradation of methylene blue by n-p heterojunction CeO<sub>2</sub>/CuS composite based on ribbon-like CeO<sub>2</sub> nanofibers via electrospinning. *Polyhedron* **2019**, *170*, 160–171. [[CrossRef](#)]
50. Shnoudeh, A.J.; Hamad, I.; Abdo, R.W.; Qadumii, L.; Jaber, A.Y.; Surchi, H.S.; Alkelany, S.Z. Chapter 15—Synthesis, Characterization, and Applications of Metal Nanoparticles. In *Biomaterials and Bionanotechnology*; Tekade, R.K., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 527–612.
51. Zarei, M.; Karimi, E.; Oskoueian, E.; Es-Haghi, A.; Yazdi, M.E.T. Comparative Study on the Biological Effects of Sodium Citrate-Based and Apigenin-Based Synthesized Silver Nanoparticles. *Nutr. Cancer* **2020**, *73*, 1511–1519. [[CrossRef](#)]
52. Jin, C.; Wang, K.; Oppong-Gyebi, A.; Hu, J. Application of Nanotechnology in Cancer Diagnosis and Therapy—A Mini-Review. *Int. J. Med. Sci.* **2020**, *17*, 2964–2973. [[CrossRef](#)] [[PubMed](#)]
53. Yazdi, M.E.T.; Amiri, M.S.; Akbari, S.; Sharifalhosseini, M.; Nourbakhsh, F.; Mashreghi, M.; Yousefi, E.; Abbasi, M.R.; Modarres, M.; Es-Haghi, A. Green Synthesis of Silver Nanoparticles Using *Helichrysum graveolens* for Biomedical Applications and Wastewater Treatment. *BioNanoScience* **2020**, *10*, 1121–1127. [[CrossRef](#)]
54. Mousavi-Kouhi, S.M.; Beyk-Khormizi, A.; Amiri, M.S.; Mashreghi, M.; Yazdi, M.E.T. Silver-zinc oxide nanocomposite: From synthesis to antimicrobial and anticancer properties. *Ceram. Int.* **2021**, *47*, 21490–21497. [[CrossRef](#)]
55. Es-Haghi, A.; Javadi, F.; Yazdi, M.E.T.; Amiri, M.S. The Expression of Antioxidant Genes and Cytotoxicity of Biosynthesized Cerium Oxide Nanoparticles against Hepatic Carcinoma Cell Line. *Avicenna J. Med Biochem.* **2019**, *7*, 16–20. [[CrossRef](#)]
56. Javadi, F.; Yazdi, M.E.T.; Baghani, M.; Es-Haghi, A. Biosynthesis, characterization of cerium oxide nanoparticles using *Ceratonia siliqua* and evaluation of antioxidant and cytotoxicity activities. *Mater. Res. Express* **2019**, *6*, 65408. [[CrossRef](#)]
57. Ahamed, M.; Akhtar, M.; Alhadlaq, H.; Alshamsan, A. Copper ferrite nanoparticle-induced cytotoxicity and oxidative stress in human breast cancer MCF-7 cells. *Colloids Surf. B Biointerfaces* **2016**, *142*, 46–54. [[CrossRef](#)] [[PubMed](#)]
58. Jana, T.K.; Jana, S.K.; Kumar, A.; De, K.; Maiti, R.; Mandal, A.K.; Chatterjee, T.; Chatterjee, B.K.; Chakrabarti, P.; Chatterjee, K. The antibacterial and anticancer properties of zinc oxide coated iron oxide nanotextured composites. *Colloids Surf. B Biointerfaces* **2019**, *177*, 512–519. [[CrossRef](#)]
59. Hu, Y.; Wang, Y. Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells. *Int. J. Nanomed.* **2012**, *7*, 2641–2652. [[CrossRef](#)]
60. Kannan, K.; Radhika, D.; Vijayalakshmi, S.; Sadasivuni, K.K.; Ojaku, A.A.; Verma, U. Facile fabrication of CuO nanoparticles via microwave-assisted method: Photocatalytic, antimicrobial and anticancer enhancing performance. *Int. J. Environ. Anal. Chem.* **2021**, 1–14. [[CrossRef](#)]
61. Naz, S.; Tabassum, S.; Fernandes, N.F.; Mujahid, M.; Zia, M.; De Blanco, E.J.C. Anticancer and antibacterial potential of *Rhus punjabensis* and CuO nanoparticles. *Nat. Prod. Res.* **2018**, *34*, 720–725. [[CrossRef](#)]